Abstract
Minodronic acid hydrate is a novel bisphosphonate with stronger anti-resorptive effects, compared to the other existing bisphosphonates. We performed additional analyses of phase III clinical trial and compared the effect of minodronic acid hydrate on bone turnover markers with those of alendronate in primary osteoporosis. The results showed that minodronic acid hydrate suppressed bone turnover early after treatment, and it also was effective in the treatment of patients with prevalent vertebral fracture, which is a high risk for subsequent fracture.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.